Bladder cancer detection in urine by novel methylation markers

Beijert, IJ; Wever, BMM; Hentschel, AE; van den Burgt, Y; Kauer, PC; Lissenberg-Witte, BI; van Moorselaar, RJA; Steenbergen, RDM; Nieuwenhuijzen, JA

Author(s): Beijert, IJ; Wever, BMM; Hentschel, AE; van den Burgt, Y; Kauer, PC; Lissenberg-Witte, BI; van Moorselaar, RJA; Steenbergen, RDM; Nieuwenhuijzen, JA;
Details: Publication Year 2024-11-20,Volume 14,Issue #1,Page 28705
Journal Title: Scientific Reports
Publication Type: Research article
Abstract: Although cystoscopy is a reliable tool for detecting bladder cancer (BC) in patients with hematuria, it is invasive, costly and often unnecessary since most patients with hematuria do not have BC. Consequently, developing urinary biomarkers for non-invasive BC detection is a major clinical need. While DNA methylation markers hold promise, diagnostic performance can still be improved. We assessed 11 candidate methylation markers for urinary BC detection. Urine samples from 77 primary BC patients and 69 controls were used for marker selection and training, with independent validation conducted on samples from 63 primary BC patients and 71 controls. Samples were self-collected at home, mailed to the hospital and analyzed via quantitative methylation-specific polymerase chain reaction. Marker performance was evaluated through univariable and multivariable logistic regression analyses. Decision curve analysis (DCA) gauged clinical utility by potential cystoscopy reduction. Evaluation identified three most promising markers: NRN1, GALR1, and HAND2. These markers exhibited significantly elevated methylation levels in BC compared to controls in both cohorts (P < 0.001). The combined marker set demonstrated an area under the curve (AUC) of 0.94 at 84% (95% CI: 76-92%) sensitivity and 96% (95% CI: 91-100%) specificity. Validation yielded nearly equivalent accuracy (AUC 0.89, sensitivity 76% (95% CI: 65-86%), specificity 93% (95% CI: 86-99%)). DCA indicated a potential of 20 to 35% reduction in cystoscopies depending on the clinical scenario. The excellent diagnostic potential of our methylation markers for non-invasive BC detection, emphasizes their significance for future diagnostic strategies.
Publisher: Springer Nature
Keywords: Humans; *Urinary Bladder Neoplasms/urine/genetics/diagnosis; Male; *DNA Methylation; Female; *Biomarkers, Tumor/urine/genetics; Aged; Middle Aged; Case-Control Studies; ROC Curve; Cystoscopy; Aged, 80 and over; Basic Helix-Loop-Helix Transcription Factors/genetics/urine; Sensitivity and Specificity; Biomarker; Bladder cancer; DNA methylation; Detection; Liquid biopsy; Urinary biomarker; Urine
Department(s): Laboratory Research
Publisher's Version: https://doi.org/10.1038/s41598-024-77781-0
Open Access at Publisher's Site: https://doi.org/10.1038/s41598-024-77781-0
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-12-10 02:43:08

Last Modified: 2024-12-10 02:54:14